Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
Open Access
- 1 September 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 3 (9), 1042-1051
- https://doi.org/10.1158/2326-6066.cir-15-0052
Abstract
Abundant macrophage infiltration of solid cancers commonly correlates with poor prognosis. Tumor-promoting functions of macrophages include angiogenesis, metastasis formation and suppression of Th1-type immune responses. We here show, that successful treatment of cervical carcinoma by synthetic long peptide (SLP) vaccines induced influx of cytokine producing CD8 T-cells that strongly altered the numbers and phenotype of intratumoral macrophages. Based on the expression of CD11b, CD11c, F4/80, Ly6C, Ly6G and MHC II we identified four myeloid subpopulations that increased in numbers from 2.0- to 8.7-fold in regressing tumors. These changes of the intratumoral myeloid composition coincided with macrophage recruitment by chemokines, including CCL2 and CCL5, and completely depended on a vaccine-induced influx of tumor-specific CD8 T-cell. CD4 T-cells were dispensable. Incubation of tumor cells with T-cell derived IFNγ and TNFα recapitulated the chemokine profile observed in vivo, confirming the capacity of anti-tumor CD8 T-cells to mediate macrophage infiltration of tumors. Strikingly, complete regressions of large established tumors depended on the tumor infiltrating macrophages that were induced by this immunotherapy, since a small drug inhibitor targeting CSF-1R diminished the number of intratumoral macrophages and abrogated the complete remissions. Survival rates after therapeutic SLP vaccination deteriorated in the presence of CSF-1R blockers. Together, these data show that therapeutic peptide vaccination induced cytokine producing T-cells that possess strong macrophage skewing capacity, required for tumor shrinkage. This warrants development of macrophage-polarizing rather than macrophage depleting agents.Keywords
Other Versions
This publication has 44 references indexed in Scilit:
- HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trialJournal of Translational Medicine, 2013
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to ChemotherapyCancer Discovery, 2011
- Tumor-associated macrophages (TAM) as major players of the cancer-related inflammationJournal of Leukocyte Biology, 2009
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of MacrophagesCancer Cell, 2009
- HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell ResponsesClinical Cancer Research, 2009
- An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activationThe Journal of Experimental Medicine, 2008
- “Re-educating” tumor-associated macrophages by targeting NF-κBThe Journal of Experimental Medicine, 2008
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- Monocyte and macrophage heterogeneityNature Reviews Immunology, 2005
- Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissuesBlood, 2004